>Probably part of the reason for the large late trade in MNTA.<
Could be, but some of the provisions in the bill might be construed as bearish for MNTA.
E.g., a worrywart might interpret the language requiring clinical trials for a FoB but allowing the FDA to waive the requirement as being harsher than merely saying that the need for clinical trials is left to the FDA’s discretion.
Market Data 
Markets 
AI
